Meredith Vanderbilt recently authored an article in the American Health Law Association’s Health Law Weekly publication titled “How the FDA Tracks Drug Shortages—and What They Might Be Missing in the GLP-1 Saga.”
In the article, Meredith examines how the FDA currently defines and monitors drug shortages, and why gaps in its tracking methods may leave critical blind spots. She explores how these shortcomings contribute to the disconnect between official reports of “resolved shortages” and the continued reality of limited patient access—an issue brought into sharp focus by the ongoing GLP-1 drug shortage.
Meredith’s analysis offers valuable insight for healthcare providers, policymakers, and industry stakeholders seeking to better understand the regulatory landscape and its real-world implications for patient care.
View a PDF of the article, or read the full article online here.
Return to Top